OBJECTIVE: To evaluate fecal calprotectin concentrations in healthy dogs and dogs with chronic diarrhea, to identify cutoff values for fecal calprotectin concentrations for use in differentiating dogs with chronic diarrhea and a canine chronic enteropathy clinical activity index (CCECAI) < 12 from dogs with chronic diarrhea and a CCECAI ≥ 12, and to evaluate the association between histologic evidence of intestinal mucosal changes and fecal calprotectin concentrations in dogs with chronic diarrhea. SAMPLE: Fecal samples from 96 adult dogs (27 dogs with chronic diarrhea and 69 healthy control dogs). PROCEDURES: Severity of clinical signs was evaluated on the basis of the CCECAI scoring system. Endoscopy was performed in all dogs with chronic diarrhea, and mucosal biopsy specimens were evaluated histologically. Fecal calprotectin concentration was quantified via radioimmunoassay. RESULTS: Fecal calprotectin concentrations were significantly higher in dogs with chronic diarrhea than in healthy control dogs. Fecal calprotectin concentrations were also significantly higher in dogs with a CCECAI ≥ 12, compared with concentrations for dogs with a CCECAI between 4 and 11. Fecal calprotectin concentrations were significantly higher in dogs with chronic diarrhea associated with histologic lesions, compared with concentrations in control dogs, and were significantly correlated with the severity of histologic intestinal lesions. Among dogs with chronic diarrhea, the best cutoff fecal calprotectin concentration for predicting a CCECAI ≥ 12 was 48.9 μg/g (sensitivity, 53.3%; specificity, 91.7%). CONCLUSIONS AND CLINICAL RELEVANCE: Fecal calprotectin may be a useful biomarker in dogs with chronic diarrhea, especially dogs with histologic lesions.
OBJECTIVE: To evaluate fecal calprotectin concentrations in healthy dogs and dogs with chronic diarrhea, to identify cutoff values for fecal calprotectin concentrations for use in differentiating dogs with chronic diarrhea and a canine chronic enteropathy clinical activity index (CCECAI) < 12 from dogs with chronic diarrhea and a CCECAI ≥ 12, and to evaluate the association between histologic evidence of intestinal mucosal changes and fecal calprotectin concentrations in dogs with chronic diarrhea. SAMPLE: Fecal samples from 96 adult dogs (27 dogs with chronic diarrhea and 69 healthy control dogs). PROCEDURES: Severity of clinical signs was evaluated on the basis of the CCECAI scoring system. Endoscopy was performed in all dogs with chronic diarrhea, and mucosal biopsy specimens were evaluated histologically. Fecal calprotectin concentration was quantified via radioimmunoassay. RESULTS: Fecal calprotectin concentrations were significantly higher in dogs with chronic diarrhea than in healthy control dogs. Fecal calprotectin concentrations were also significantly higher in dogs with a CCECAI ≥ 12, compared with concentrations for dogs with a CCECAI between 4 and 11. Fecal calprotectin concentrations were significantly higher in dogs with chronic diarrhea associated with histologic lesions, compared with concentrations in control dogs, and were significantly correlated with the severity of histologic intestinal lesions. Among dogs with chronic diarrhea, the best cutoff fecal calprotectin concentration for predicting a CCECAI ≥ 12 was 48.9 μg/g (sensitivity, 53.3%; specificity, 91.7%). CONCLUSIONS AND CLINICAL RELEVANCE: Fecal calprotectin may be a useful biomarker in dogs with chronic diarrhea, especially dogs with histologic lesions.
Authors: Romy M Heilmann; Melissa M Guard; Linda Toresson; Stefan Unterer; Aurélien Grellet; Niels Grützner; Jan S Suchodolski; Joerg M Steiner Journal: Vet Med Sci Date: 2021-03-10
Authors: Mohsen Hanifeh; Romy M Heilmann; Satu Sankari; Minna M Rajamäki; Laura Mäkitalo; Pernilla Syrjä; Susanne Kilpinen; Jan S Suchodolski; Jörg M Steiner; Thomas Spillmann Journal: BMC Vet Res Date: 2015-09-14 Impact factor: 2.741
Authors: A Grellet; R M Heilmann; B Polack; A Feugier; C Boucraut-Baralon; D Grandjean; N Grützner; J S Suchodolski; J M Steiner; S Chastant-Maillard Journal: J Vet Intern Med Date: 2016-06-08 Impact factor: 3.333
Authors: Magda Gerou-Ferriani; Rhiannon Allen; Peter-John M Noble; Alexander J German; Marco Caldin; Daniel J Batchelor Journal: J Vet Intern Med Date: 2018-04-16 Impact factor: 3.333
Authors: Cristiane C Otoni; Romy M Heilmann; Mercedes García-Sancho; Angel Sainz; Mark R Ackermann; Jan S Suchodolski; Jörg M Steiner; Albert E Jergens Journal: J Vet Intern Med Date: 2018-04-06 Impact factor: 3.333
Authors: Romy M Heilmann; Nora Berghoff; Joanne Mansell; Niels Grützner; Nolie K Parnell; Corinne Gurtner; Jan S Suchodolski; Jörg M Steiner Journal: J Vet Intern Med Date: 2018-02-20 Impact factor: 3.333
Authors: Michelle C Coleman; Canaan Whitfield-Cargile; Noah D Cohen; Jennifer L Goldsby; Laurie Davidson; Ana M Chamoun-Emanuelli; Ivan Ivanov; Susan Eades; Nancy Ing; Robert S Chapkin Journal: PLoS One Date: 2020-03-16 Impact factor: 3.240